| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 650 | 1,770 | 2,820 | 5,420 |
| Sales Growth | -100.00% | -63.28% | -37.23% | -47.97% | +136.68% |
| Net Income | -13,000 | -18,400 | 47,760 | -35,100 | -40,380 |
| Net Income Growth | +29.35% | -138.53% | +236.07% | +13.08% | +24.15% |
Talphera Inc (TLPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Talphera Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate consists Niyad(TM). Talphera Inc., formerly known as AcelRx Pharmaceuticals Inc., is based in SAN MATEO, Calif.
Fiscal Year End Date: 12/31